So far, several researches reveal that Ki-67 automatic counting systems and individual platforms, such as Immuno Path and Immuno Ratio softwares, have been developed and further utilized in lung cancer, pancreatic cancer, lymphoma, breast cancer, and other tumors [23, 24]. This evidence concerns the gene MKI67 and familial pancreatic carcinoma.